Norovirus is the most common reason of viral gastroenteritis in humans. It affects around 700 million people worldwide each year. Health care cost more than $4 billion a year and cost jumps further to $64 billion in the condition of lost productivity and other societal costs.
Norovirus can cause symptoms such as nausea, fever, diarrhea and vomiting. There is no specific vaccine or treatment to treat infected people with norovirus illness and no cure in antibiotics because it is not a bacterial infection.
The study was published online in the journal PLOS One, shows the need for continuous efforts to prevent the disease, the researchers said.
This Norovirus needs more attention because the costs related with this virus are extremely higher than for many diseases includes rotavirus. India may not have faced hard times with the Zika virus but it was a Biotech moment for India for developing a vaccine, which huge western pharma giants couldn’t – India’s Biotech Moment.
The researchers said, the first is the findings to evaluate the global economic effect of the highly contagious virus (can transmit from person to another), which is common in both poor and rich nations.
The preventive measure of Norovirus involves:
- Proper hand washing & disinfectants
- Food Safety (While preparing food)
- Improving water sources
- Keeping sick people(norovirus)away from others
This Norovirus affects people of all ages and all kind of people so we need to focus and teach people the preventive measures, Bartsch (Research Associate) said in a Hopkins news release.
India Medical Device Pricing Strategy: Ensuring Growth & Affordability
India’s National Pharmaceutical Pricing Authority (NPPA) is developing a specialized India medical device pricing strategy for medical devices, transitioning away from the conventional drug-centric framework. This innovative strategy will incorporate international pricing tactics tailored to […]
Read MoreImports of High-Value Medical Equipment
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC Committee: Pioneering Medical Approvals
New important article released by Central Drugs Standard Control Organization (CDSCO) titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing materials, […]
Read MoreErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read MoreTUV SUD Inspects IVD Medical Devices’ Cyber Security
The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]
Read More